TRANSMEDICS GROUP INC (TMDX)
US89377M1099 - Common Stock
TMDX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 196 industry peers in the Health Care Equipment & Supplies industry. While TMDX seems to be doing ok healthwise, there are quite some concerns on its profitability. TMDX shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year TMDX has reported negative net income.
TMDX had a negative operating cash flow in the past year.
TMDX had negative earnings in each of the past 5 years.
In the past 5 years TMDX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.54%, TMDX is in the better half of the industry, outperforming 65.31% of the companies in the same industry.
TMDX has a better Return On Equity (-18.24%) than 61.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.54% | ||
| ROE | -18.24% | ||
| ROIC | N/A |
ROA(3y)-16.47%
ROA(5y)-20.03%
ROE(3y)-34.23%
ROE(5y)-38.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX's Gross Margin of 63.77% is fine compared to the rest of the industry. TMDX outperforms 63.78% of its industry peers.
TMDX's Gross Margin has improved in the last couple of years.
TMDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5Y7.7%
2. Health
2.1 Basic Checks
TMDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TMDX has more shares outstanding
The number of shares outstanding for TMDX has been increased compared to 5 years ago.
Compared to 1 year ago, TMDX has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.00 indicates that TMDX is not in any danger for bankruptcy at the moment.
The Altman-Z score of TMDX (3.00) is better than 67.35% of its industry peers.
A Debt/Equity ratio of 3.69 is on the high side and indicates that TMDX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.69, TMDX is doing worse than 88.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.69 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3 |
ROIC/WACCN/A
WACC9.59%
2.3 Liquidity
TMDX has a Current Ratio of 9.30. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 9.30, TMDX belongs to the best of the industry, outperforming 89.80% of the companies in the same industry.
TMDX has a Quick Ratio of 8.49. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TMDX (8.49) is better than 90.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.3 | ||
| Quick Ratio | 8.49 |
3. Growth
3.1 Past
TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.40%, which is quite impressive.
TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 158.53%.
TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.35% yearly.
EPS 1Y (TTM)38.4%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q157.14%
Revenue 1Y (TTM)158.53%
Revenue growth 3Y111.22%
Revenue growth 5Y79.35%
Revenue growth Q2Q158.68%
3.2 Future
TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 70.01% yearly.
The Revenue is expected to grow by 37.92% on average over the next years. This is a very strong growth
EPS Next Y70.06%
EPS Next 2Y55.69%
EPS Next 3Y70.01%
EPS Next 5YN/A
Revenue Next Year60.64%
Revenue Next 2Y46.45%
Revenue Next 3Y40.99%
Revenue Next 5Y37.92%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TMDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TMDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 70.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.69%
EPS Next 3Y70.01%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRANSMEDICS GROUP INC
NASDAQ:TMDX (4/19/2024, 4:26:07 PM)
After market: 84.16 0 (0%)84.16
-3.08 (-3.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.75B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.54% | ||
| ROE | -18.24% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.77% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.69 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.3 | ||
| Quick Ratio | 8.49 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)38.4%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y70.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)158.53%
Revenue growth 3Y111.22%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y